Loading
MAML2 (Mastermind-like protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Vulvar cancer, Breast cancer and 5 more.
Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3.
Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes literature 0.91, affected pathway 0.94, genetic association 0.31, somatic mutation 0.89). IntOGen calls it a driver in 3 cohorts (0 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia, Lung Squamous Cell Carcinoma, Vulva/Vagina.
In plain words · MAML2 (Mastermind-like protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Vulvar cancer, Breast cancer and 5 more.
MAML2 (Mastermind-like protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Vulvar cancer, Breast cancer and 5 more.
Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1.
No product in this corpus aims at MAML2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 2001. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 2001, "Prediction of the coding sequences of unidentified human genes. XX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:16259 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8IZL2 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000184384 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, skin cancer 0.52, breast cancer 0.55, lung cancer 0.60, oral cavity cancer 0.56, mucoepidermoid carcinoma 0.58 (GraphQL API, CC0)); IntOGen MAML2 (driver in 3 cohorts (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3. Location: Nucleus speckle (UniProt). Locus 11q21 (HGNC).
Query for this target: (TITLE:"MAML2" OR ABSTRACT:"MAML2" OR TITLE:"mastermind like transcriptional coactivator 2" OR ABSTRACT:"mastermind like transcriptional coactivator 2" OR TITLE:"Mastermind-like protein 2" OR ABSTRACT:"Mastermind-like protein 2" OR TITLE:"KIAA1819" OR ABSTRACT:"KIAA1819" OR TITLE:"MAM3" OR ABSTRACT:"MAM3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAML2, not a curated reading list.
Shares Mucoepidermoid carcinoma, Oral cavity cancer (mouth and tongue), Skin cancer (all types), IntOGen.
Shares Vulvar cancer, Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Oral cavity cancer (mouth and tongue), IntOGen, Breast cancer (all types), Open Targets Platform.
Shares Oral cavity cancer (mouth and tongue), Breast cancer (all types), Open Targets Platform.
Shares Oral cavity cancer (mouth and tongue), Breast cancer (all types), Open Targets Platform.
Shares Oral cavity cancer (mouth and tongue), Breast cancer (all types), Open Targets Platform.
Shares Oral cavity cancer (mouth and tongue), Skin cancer (all types), Breast cancer (all types), Open Targets Platform.
Shares Vulvar cancer, IntOGen, Breast cancer (all types), Open Targets Platform.